Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMGN NASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shsN/AMLTXMoonLake Immunotherapeutics$17.06-0.8%$17.47$5.95▼$62.75$1.23B1.01779,663 shs961,583 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMGNImmunoGen0.00%0.00%0.00%0.00%0.00%MLTXMoonLake Immunotherapeutics0.00%+5.01%-7.53%+10.90%-54.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shsN/AMLTXMoonLake Immunotherapeutics$17.06-0.8%$17.47$5.95▼$62.75$1.23B1.01779,663 shs961,583 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMGNImmunoGen0.00%0.00%0.00%0.00%0.00%MLTXMoonLake Immunotherapeutics0.00%+5.01%-7.53%+10.90%-54.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMGNImmunoGen 0.00N/AN/AN/AMLTXMoonLake Immunotherapeutics 2.38Hold$23.0835.27% UpsideCurrent Analyst Ratings BreakdownLatest MLTX and IMGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/30/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.003/23/2026MLTXMoonLake Immunotherapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Outperform$12.00 ➝ $24.003/19/2026MLTXMoonLake Immunotherapeutics Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$12.00 ➝ $40.003/2/2026MLTXMoonLake Immunotherapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$12.00 ➝ $13.003/2/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $40.002/24/2026MLTXMoonLake Immunotherapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$30.00 ➝ $35.002/24/2026MLTXMoonLake Immunotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold2/23/2026MLTXMoonLake Immunotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.002/23/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $30.002/20/2026MLTXMoonLake Immunotherapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$10.00 ➝ $12.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMGNImmunoGen$287.61M28.91N/AN/A$0.71 per share43.99MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMGNImmunoGen-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/AMLTXMoonLake Immunotherapeutics-$227.32M-$3.52N/AN/AN/AN/A-66.56%-50.23%5/11/2026 (Estimated)Latest MLTX and IMGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91N/AN/AN/AN/AN/A2/25/2026Q4 2025MLTXMoonLake Immunotherapeutics-$0.92-$0.92N/A-$0.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMGNImmunoGenN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMGNImmunoGen0.135.705.65MLTXMoonLake Immunotherapeutics0.249.279.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMGNImmunoGen90.50%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipIMGNImmunoGen5.07%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMGNImmunoGen277266.26 million252.76 millionNo DataMLTXMoonLake Immunotherapeutics271.73 million63.11 millionOptionableMLTX and IMGN HeadlinesRecent News About These CompaniesMoonLake Immunotherapeutics (MLTX) to Release Earnings on MondayMay 4, 2026 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from BrokeragesMay 2, 2026 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from BrokeragesMay 2, 2026 | marketbeat.comShort Interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) Decreases By 14.2%May 1, 2026 | marketbeat.comThe CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?April 18, 2026 | fool.comMoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Sells $945,644.79 in StockApril 15, 2026 | insidertrades.comMajor Insider Move at MoonLake Immunotherapeutics Stirs Investor AttentionApril 14, 2026 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 51,873 SharesApril 14, 2026 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 98,127 SharesApril 14, 2026 | marketbeat.comPositive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake ImmunotherapeuticsApril 14, 2026 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 6% - Here's WhyApril 10, 2026 | marketbeat.comJPMorgan Chase & Co. Buys 134,764 Shares of MoonLake Immunotherapeutics $MLTXApril 10, 2026 | marketbeat.comBiotech Fund BVF Trims MoonLake Stake, Sells $63M in SharesApril 7, 2026 | fool.comHow Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis SuppurativaApril 5, 2026 | finance.yahoo.comInsider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) Director Sells 3,750,000 Shares of StockApril 3, 2026 | insidertrades.comMajor Insider Move at MoonLake Immunotherapeutics Shakes Up Investor SentimentApril 2, 2026 | tipranks.comWhy MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 7.24%April 2, 2026 | aaii.comAMoonLake ImmunotherapeuticsApril 1, 2026 | marketwatch.comH.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)March 31, 2026 | theglobeandmail.comMLTX stock garners retail attention on buyout speculation, positive skin condition trial dataMarch 31, 2026 | msn.comMLTX stock jumps overnight: lead skin disease drug delivers strong phase 3 gains with majority of patients improvingMarch 30, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMLTX and IMGN Company DescriptionsImmunoGen NASDAQ:IMGNImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.MoonLake Immunotherapeutics NASDAQ:MLTX$17.06 -0.14 (-0.81%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$17.05 -0.01 (-0.09%) As of 05/8/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
